All In MedTech

Device Trial Radar · NCT00180349

Leader - Evaluation of Endotak Reliance

Short and Long Term Evaluation of Electrical Measurements and Defibrillation Energies, Results of ATP and Diagnostic Functions of Devices Connected to Endotak RELIANCE® Defibrillation Leads

Last checked: Nov 20, 2026Latest source record: Apr 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

904

Actual

Start

Dec 2004

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Sep 16, 2005

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to demonstrate the efficacy of the ENDOTAK® RELIANCE™ defibrillation leads connected to a defibrillator or a cardiac resynchronization defibrillator from implant until 12 months.

Conditions

  • Ventricular Tachycardia
  • Ventricular Fibrillation

Interventions

  • Endotak RelianceDevice

    Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Defibrillation testing (DT) procedures and consequences on clinical outcomesTime frame: at implant
  2. Defibrillation testing (DT) procedures and consequences on clinical outcomesTime frame: during 1 year follow-up

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • CH Amiens

    Amiens, France

  • CHU Angers

    Angers, France

  • Hôpital Angoulème

    Angoulème, France

22 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.